Typhlitis Risk Factors and Clinical Context

Primary High-Risk Populations

Acute myelogenous leukemia patients represent the highest risk group, especially those receiving high-dose cytosine arabinoside (Ara-C) chemotherapy, with typhlitis typically developing 1-2 weeks after chemotherapy initiation, during the period of maximal mucosal damage and neutropenia 1
Approximately 6.5% of neutropenic patients undergoing myelosuppressive therapy develop neutropenic enterocolitis, with the real incidence ranging from 0.8% to 26% across cancer populations 1
Solid organ cancer patients receiving high-dose chemotherapy can develop typhlitis 1
The American College of Surgeons recommends considering typhlitis in patients with severe neutropenia following chemotherapy for hematologic malignancies, particularly acute myelogenous leukemia 1

Solid organ transplant patients, particularly kidney transplant recipients, are at risk due to chronic immunosuppression with medications like prednisone and cyclosporine, with moderate to severe immunocompromise that predisposes to neutropenic enterocolitis 2
Patients with HIV who have progressed to AIDS represent an acquired immunodeficiency state that increases typhlitis risk, with the combination of HIV-related immunosuppression and potential concurrent medications creating vulnerability 2

Severe neutropenia is the hallmark risk factor, with typhlitis occurring during the nadir of white blood cell counts following chemotherapy, typically manifesting during the second to third week after chemotherapy initiation 1
Resolution directly correlates with recovery of neutrophil counts 1
Chronic corticosteroid therapy increases risk, according to the World Journal of Emergency Surgery 2

Patients with bowel wall thickening >10mm on CT imaging have a 60% mortality risk, indicating advanced disease, with mortality in patients with radiologic signs of neutropenic enteritis reaching 29.5% even with appropriate treatment 1
The World Health Organization recommends considering the severity of neutropenic enterocolitis when assessing mortality risk, with bowel wall thickening being a key indicator 1